ZBTB20-AS1

Across TCGA pan-cancer cohorts, ZBTB20-AS1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of ZBTB20-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ZBTB20-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZBTB20-AS1 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

KIRC, HNSC, and LIHC are the cancer types where ZBTB20-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZBTB20-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.083	<.001	8	view →
HNSC	All	All	+0.059	<.001	7	view →
LIHC	All	II,III,IV	+0.084	.002	5	view →
CHOL	All	All	+0.273	<.001	4	view →
LUAD	All	All	+0.277	.043	2	view →
BRCA	All	All	+0.160	.034	2	view →
THCA	All	All	−0.069	.027	2	view →
LUSC	Male	III,IV	−0.235	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

ZBTB20-AS1–KIRC

Open the KIRC breakdown →